Connection

Joseph Schacht to Humans

Back to Details
This is a "connection" page, showing publications Joseph Schacht has written about Humans.
Joseph Schacht
Connection Strength
0.472
Humans
  1. Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone. Neuropsychopharmacology. 2022 10; 47(11):1953-1960.
    View in: PubMed
    Score: 0.031
  2. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.029
  3. Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesth Analg. 2021 02 01; 132(2):305-307.
    View in: PubMed
    Score: 0.028
  4. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
    View in: PubMed
    Score: 0.027
  5. The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms. Addict Biol. 2019 09; 24(5):1109-1118.
    View in: PubMed
    Score: 0.024
  6. Parsing Cannabis Exposure and Predisposing Risk Effects: Does Adolescent Cannabis Use Cause Neurocognitive Impairment, or Result From It? Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 08; 3(8):654-656.
    View in: PubMed
    Score: 0.024
  7. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.023
  8. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
    View in: PubMed
    Score: 0.023
  9. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
    View in: PubMed
    Score: 0.022
  10. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. Pharmacogenomics J. 2016 10; 16(5):430-8.
    View in: PubMed
    Score: 0.020
  11. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep; 231(18):3799-807.
    View in: PubMed
    Score: 0.018
  12. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
    View in: PubMed
    Score: 0.016
  13. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.016
  14. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology. 2012 Oct; 37(11):2368-76.
    View in: PubMed
    Score: 0.015
  15. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2013 Jan; 18(1):121-33.
    View in: PubMed
    Score: 0.015
  16. Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
    View in: PubMed
    Score: 0.014
  17. Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage. 2011 May 01; 56(1):61-8.
    View in: PubMed
    Score: 0.014
  18. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berl). 2009 Apr; 203(3):511-7.
    View in: PubMed
    Score: 0.012
  19. A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nat Protoc. 2022 03; 17(3):567-595.
    View in: PubMed
    Score: 0.008
  20. Clinical and Neural Correlates of Reward and Relief Drinking. Alcohol Clin Exp Res. 2021 01; 45(1):194-203.
    View in: PubMed
    Score: 0.007
  21. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
    View in: PubMed
    Score: 0.007
  22. Intraindividual changes in brain GABA, glutamate, and glutamine during monitored abstinence from alcohol in treatment-naive individuals with alcohol use disorder. Addict Biol. 2020 11; 25(6):e12810.
    View in: PubMed
    Score: 0.006
  23. Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment na?ve individuals with alcohol use disorder. Neurosci Lett. 2019 07 27; 706:207-210.
    View in: PubMed
    Score: 0.006
  24. Preliminary evidence that computerized approach avoidance training is not associated with changes in fMRI cannabis cue reactivity in non-treatment-seeking adolescent cannabis users. Drug Alcohol Depend. 2019 07 01; 200:145-152.
    View in: PubMed
    Score: 0.006
  25. Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Na?ve Individuals with Alcohol Use Disorder Versus Light Drinkers. Alcohol Clin Exp Res. 2019 02; 43(2):221-226.
    View in: PubMed
    Score: 0.006
  26. Investigating a novel fMRI cannabis cue reactivity task in youth. Addict Behav. 2019 02; 89:20-28.
    View in: PubMed
    Score: 0.006
  27. Earlier alcohol use onset prospectively predicts changes in functional connectivity. Psychopharmacology (Berl). 2018 04; 235(4):1041-1054.
    View in: PubMed
    Score: 0.006
  28. Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. Alcohol Clin Exp Res. 2017 Jul; 41(7):1370-1380.
    View in: PubMed
    Score: 0.005
  29. Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol. 2016 Sep; 51(5):549-54.
    View in: PubMed
    Score: 0.005
  30. The Reasons for Heavy Drinking Questionnaire: Factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs. 2016 Mar; 77(2):354-61.
    View in: PubMed
    Score: 0.005
  31. Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res. 2016 Mar; 40(3):491-6.
    View in: PubMed
    Score: 0.005
  32. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol. 2016 Jan; 21(1):3-22.
    View in: PubMed
    Score: 0.005
  33. Pharmacologic treatment of alcoholism. Handb Clin Neurol. 2014; 125:527-42.
    View in: PubMed
    Score: 0.004
  34. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology. 2010 Mar; 35(4):967-75.
    View in: PubMed
    Score: 0.003
  35. Marijuana craving in the brain. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):13016-21.
    View in: PubMed
    Score: 0.003
  36. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction. 2008 Oct; 103(10):1678-86.
    View in: PubMed
    Score: 0.003
  37. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry. 2008 Jul; 65(7):841-50.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.